ReviewCurrent opinion in rheumatology2012
Renal disease in scleroderma: an update on evaluation, risk stratification, pathogenesis and management.
Review in Current opinion in rheumatology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 105 citations in OpenAlex.
- Secondary Membranous Nephropathy. A Narrative Review.Frontiers in medicine · 2020Pooled it
- Bibliometric insights into systemic sclerosis with renal involvement: trends, contributions, and future directions.Renal failure · 2025Article
- Cardiac tamponade with scleroderma renal crisis in systemic sclerosis: a case report.Annals of medicine and surgery (2012) · 2025Article
- Analysis of related deaths in patients with systemic sclerosis combined with renal failure in the United States from 1999 to 2020.Scientific reports · 2025Article
- Light Chain (AL) Amyloidosis Masquerading as Scleroderma: A Diagnostic Challenge.Journal of hematology · 2025Article
- Scleroderma renal crisis, an increasingly rare but persistently challenging condition: a retrospective cohort study.Rheumatology advances in practice · 2024Article
- Risk of kidney failure in patients with systemic sclerosis: a nationwide population-based study.RMD open · 2023Article
- Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers.Clinical reviews in allergy & immunology · 2023Article
- Evaluation of hypertension in systemic sclerosis and systemic lupus erythematosus overlap.Journal of scleroderma and related disorders · 2023Review
- Lung-kidney interactions and their role in chronic kidney disease-associated pulmonary diseases.American journal of physiology. Lung cellular and molecular physiology · 2022Review
- Cutaneous manifestations of acute kidney injury.Clinical kidney journal · 2022Review
- Echocardiographic measures and subsequent decline in kidney function in older adults: the Atherosclerosis Risk in Communities Study.European heart journal. Cardiovascular Imaging · 2022Article
- Kidney transplantation in systemic sclerosis: Advances in graft, disease, and patient outcome.Frontiers in immunology · 2022Review
- Prognostic Role of Measurement of Renal Resistive Index in Systemic Sclerosis.Mediterranean journal of rheumatology · 2021Article
- Journey of a patient with scleroderma from renal failure up to kidney transplantation.World journal of transplantation · 2021Review
- Serum and urine free light chains measurements in patients with systemic sclerosis: novel biomarkers for disease activity.Clinical and experimental immunology · 2021Article
- Scleroderma renal crisis: Case reports and update on critical issues.European journal of rheumatology · 2021Article
- Progression of gastrointestinal symptoms over time in patients with systemic sclerosis.Rheumatology international · 2021Article
- ANCA-associated vasculitis overlaps with systemic sclerosis: a case report and literature review.European journal of medical research · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewRenal disease remains an important cause of morbidity and mortality in scleroderma. The spectrum of renal complications in systemic sclerosis includes scleroderma renal crisis (SRC), normotensive renal crisis, antineutrophil cytoplasmic antibodies-associated glomerulonephritis, penacillamine-associated renal disease, and reduced renal functional reserves manifested by proteinuria, microalbuminuria, or isolated reduction in glomerular filtration rate. The purpose of this review is to provide a concise and up-to-date review of the evaluation, risk stratification, pathogenesis, and management of scleroderma-associated renal disease. RECENT
findingsAlthough SRC survival has significantly improved, mortality of this complication remains high outside of specialized centers. Recent data demonstrate strong associations between anti-RNA polymerase III antibodies and SRC. Subclinical renal impairment affects approximately 50% of scleroderma patients and may be associated with other vascular manifestations. Subclinical renal involvement rarely progresses to end-stage renal failure; however, recent studies suggest it may predict mortality in patients with other vasculopathic manifestations. SUMMARY: Testing for anti-RNA polymerase III antibodies should be incorporated into clinical care to identify patients at high risk for SRC. Recommendations from European League Against Rheumatism (EULAR), EULAR Scleroderma Trials and Research, and the Scleroderma Clinical Trials Consortium confirm angiotensin-converting enzyme inhibitors as first-line therapy for SRC, and give recommendations for second-line agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.